QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
NYSEAMERICAN:STXS

Stereotaxis (STXS) Stock Price, News & Analysis

$2.50
+0.05 (+2.04%)
(As of 01:57 PM ET)
Today's Range
$2.45
$2.54
50-Day Range
N/A
52-Week Range
$1.33
$3.29
Volume
82,276 shs
Average Volume
307,727 shs
Market Capitalization
$205.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Stereotaxis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.5% Upside
$4.50 Price Target
Short Interest
Healthy
1.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Stereotaxis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.23) to ($0.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.60 out of 5 stars

STXS stock logo

About Stereotaxis Stock (NYSEAMERICAN:STXS)

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

STXS Stock Price History

STXS Stock News Headlines

Stereotaxis Inc.
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
7 Penny Stocks That Could 5X by the End of 2024
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Recap: Stereotaxis Q4 Earnings
Stereotaxis Reports 2023 Full Year Financial Results
Stereotaxis Q4 2023 Earnings Preview
Earnings Preview For Stereotaxis
Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)
Stereotaxis Inc STXS
See More Headlines
Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:STXS
CIK
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$5.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+83.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-20,710,000.00
Pretax Margin
-77.37%

Debt

Sales & Book Value

Annual Sales
$26.77 million
Book Value
$0.20 per share

Miscellaneous

Free Float
66,919,000
Market Cap
$201.22 million
Optionable
Not Optionable
Beta
1.34
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

STXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Stereotaxis stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STXS shares.
View STXS analyst ratings
or view top-rated stocks.

What is Stereotaxis' stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for Stereotaxis' shares. Their STXS share price targets range from $4.00 to $5.00. On average, they expect the company's share price to reach $4.50 in the next year. This suggests a possible upside of 81.5% from the stock's current price.
View analysts price targets for STXS
or view top-rated stocks among Wall Street analysts.

How have STXS shares performed in 2024?

Stereotaxis' stock was trading at $2.87 at the start of the year. Since then, STXS stock has decreased by 13.6% and is now trading at $2.48.
View the best growth stocks for 2024 here
.

How were Stereotaxis' earnings last quarter?

Stereotaxis, Inc. (NYSEAMERICAN:STXS) released its quarterly earnings data on Monday, March, 4th. The company reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). The company had revenue of $4.57 million for the quarter, compared to analyst estimates of $7.55 million. Stereotaxis had a negative trailing twelve-month return on equity of 103.37% and a negative net margin of 77.37%.

What guidance has Stereotaxis issued on next quarter's earnings?

Stereotaxis issued an update on its first quarter 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $6.7 million.

Who are Stereotaxis' major shareholders?

Stereotaxis' stock is owned by many different institutional and retail investors. Top institutional investors include GSG Advisors LLC (0.03%).
View institutional ownership trends
.

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:STXS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners